Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q4 FY20 results · Jan–Mar 2020
Procter & Gamble Health reported revenue from operations of ₹228.11 crore (down 1.3% from Q4 FY19) and net profit of ₹46.46 crore (up 14.1% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a standalone basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 228.11 | 231.03 | −1.3% | 236.77 | −3.7% |
| Other income | 10.26 | 17.69 | −42.0% | 6.06 | +69.4% |
| Total income | 238.37 | 248.72 | −4.2% | 242.82 | −1.8% |
| Profit before tax | 64.76 | 63.49 | +2.0% | 50.80 | +27.5% |
| Net profit for the period | 46.46 | 40.71 | +14.1% | 38.21 | +21.6% |
| EPS, basic (₹) | 27.99 | 24.52 | +14.2% | 23.02 | +21.6% |
| Net margin (%) | 20.4 | 17.6 | 16.1 |
Standalone
- Filed with BSE
- 05 Jun 2020, 16:19 IST
- Board meeting
- 29 May 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE